Skip to content
Screener

MapLight Therapeutics, Inc. MPLT Q1 2026 earnings

Reported August 13, 2026 · After market close

EPS-$1.32Beat by $0.03
EPS estimate-$1.35

Next report

Sep 18, 2026 (In 3 weeks)
EPS estimate-$1.35

Financials

Q1 2026

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M—
Total debt$5.6M—
Total equity$399.8M+285%
Total assets$418.8M—

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K—
Free cash flow-$51.2M—

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$596.42M-14.1%
Enterprise value$546.3M—

Returns & leverage

See full
Debt / equity0×—
Current ratio22.9×—

Versus estimates

Diluted EPS

Q1 2026-$1.32Beat by $0.03
Q4 2025-$1.34Miss by $0.38Q3 2025-$37.18Miss by $35.46

FAQ

When did MapLight Therapeutics, Inc. report Q1 2026 earnings?
MapLight Therapeutics, Inc. (MPLT) reported Q1 2026 earnings on August 13, 2026 after market close.
What were MapLight Therapeutics, Inc.'s Q1 2026 revenue and EPS?
MapLight Therapeutics, Inc. reported eps of $-1.32 for Q1 2026.
Did MapLight Therapeutics, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-1.35 by $0.03.
Where can I find MapLight Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-349490) and the 10-Q periodic report (0001193125-26-224129) directly on SEC EDGAR. The filing index links above go to sec.gov.